NW Bio Announces financings Totalling $35 Million to Expand and Accelerate DCVax-L and DCVax-Direct Programs

Funding Includes $25 Million Equity Investment By Leading UK Investment Fundand $10 Million Mortgage Financing BETHESDA, Md., Nov. 19, 2014 /PRNewswire/ — Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today two financings totaling $35 million.  The financings include a $25 million equity investment by UK based C.F. Woodford Equity …

NW Bio Announces German Early Access and Reimbursement Approvals for DCVax-L

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator March 10, 2014  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute (“PEI”- the FDA of Germany) of a “Hospital Exemption” early access program under Section 4b of the …